Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentin Harter

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Annales De Pathologie|December 3, 2017
[FREGAT: French clinico-biological database dedicated to esogastric cancers]Florence Renaud, Frédéric Bibeau, Emmanuelle Leteurtre, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 29, 2012
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective studyClaire Charra-Brunaud, Valentin Harter, Martine Delannes, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 1, 2025
Time to reconsider the use of synthetic mesh in immediate prepectoral implant-based breast reconstruction: Impact of their use on short-term outcomesEléa Leroy, Laura Poirier, Hélène Planque, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancer Medicine|October 18, 2013
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancerAnne-Sophie Chretien, Alexandre Harlé, Magali Meyer-Lefebvre, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER TrialChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancers|March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Clémentine Krucker, et al.
Brachytherapy|June 21, 2014
Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancerSabrina Boyrie, Claire Charra-Brunaud, Valentin Harter, et al.
Bioinformatics (Oxford, England)|October 17, 2019
SpliceLauncher: a tool for detection, annotation and relative quantification of alternative junctions from RNAseq dataRaphaël Leman, Valentin Harter, Alexandre Atkinson, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Annales De Pathologie|December 3, 2017
[FREGAT: French clinico-biological database dedicated to esogastric cancers]Florence Renaud, Frédéric Bibeau, Emmanuelle Leteurtre, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 29, 2012
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective studyClaire Charra-Brunaud, Valentin Harter, Martine Delannes, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 1, 2025
Time to reconsider the use of synthetic mesh in immediate prepectoral implant-based breast reconstruction: Impact of their use on short-term outcomesEléa Leroy, Laura Poirier, Hélène Planque, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancer Medicine|October 18, 2013
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancerAnne-Sophie Chretien, Alexandre Harlé, Magali Meyer-Lefebvre, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER TrialChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancers|March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Clémentine Krucker, et al.
Brachytherapy|June 21, 2014
Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancerSabrina Boyrie, Claire Charra-Brunaud, Valentin Harter, et al.
Bioinformatics (Oxford, England)|October 17, 2019
SpliceLauncher: a tool for detection, annotation and relative quantification of alternative junctions from RNAseq dataRaphaël Leman, Valentin Harter, Alexandre Atkinson, et al.
Pageof 3